Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances

被引:326
作者
Gandhi, Nishant S. [1 ]
Tekade, Rakesh K. [1 ,2 ]
Chougule, Mahavir B. [1 ,3 ]
机构
[1] Univ Hawaii, Daniel K Inouye Coll Pharm, Dept Pharmaceut Sci, Hilo, HI 96720 USA
[2] Univ Texas SW Med Ctr Dallas, Preclin Nucl Imaging Lab, Dallas, TX 75390 USA
[3] Univ Hawaii, Ctr Canc, Nat Prod & Expt Therapeut Program, Honolulu, HI 96822 USA
基金
美国国家卫生研究院;
关键词
Nanotechnology; Cancer; siRNA; miRNA; Combination therapy; Clinical trial; MESOPOROUS SILICA NANOPARTICLES; OVERCOME DRUG-RESISTANCE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLES; TUMOR-TARGETED DELIVERY; INNATE IMMUNE-RESPONSE; MESENCHYMAL STEM-CELLS; TOLL-LIKE RECEPTORS; DOUBLE-STRANDED-RNA; CO-DELIVERY;
D O I
10.1016/j.jconrel.2014.09.001
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibit drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms, etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), multidrug resistant protein 1 (MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:238 / 256
页数:19
相关论文
共 233 条
[1]
The Bcl-2 apoptotic switch in cancer development and therapy [J].
Adams, J. M. ;
Cory, S. .
ONCOGENE, 2007, 26 (09) :1324-1337
[2]
Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation [J].
Ahmed, Fariyal ;
Pakunlu, Refika I. ;
Srinivas, Goundla ;
Brannan, Aaron ;
Bates, Frank ;
Klein, Michael L. ;
Minko, Tamara ;
Discher, Dennis E. .
MOLECULAR PHARMACEUTICS, 2006, 3 (03) :340-350
[3]
Nonviral delivery of synthetic siRNAs in vivo [J].
Akhtar, Saghir ;
Benter, Ibrahim F. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3623-3632
[4]
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis [J].
Akinc, A ;
Thomas, M ;
Klibanov, AM ;
Langer, R .
JOURNAL OF GENE MEDICINE, 2005, 7 (05) :657-663
[5]
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[6]
Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[7]
RISING CHEMICAL STARS COULD PLAY MANY ROLES [J].
ALPER, J .
SCIENCE, 1991, 251 (5001) :1562-1564
[8]
Chitosan based nanocarriers for indomethacin ocular delivery [J].
Badawi, Alia A. ;
El-Laithy, Hanan M. ;
El Qidra, Riad K. ;
El Mofty, Hala ;
El Dally, Mohamed .
ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (08) :1040-1049
[9]
Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study [J].
Bai, Shuhua ;
Gupta, Vivek ;
Ahsan, Fakhrul .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 38 (02) :165-171
[10]
MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29